Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHQ6KT)

Drug Name

PHA-666859 Drug Info

Synonyms

SC-409; SD-0006; P38-alpha kinase inhibitor (inflammation/diabetic retinopathy); P38-alpha kinase inhibitor (inflammation/diabetic retinopathy), Pfizer

Indication

Disease Entry	ICD 11	Status	REF
Diabetic retinopathy	9B71.0	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMHQ6KT
VARIDT Drug ID: DR00736

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[2]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[2]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[3]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[4]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[2]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
2	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
3	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
4	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
5	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.